Compare Amphastar Pharmaceuticals Inc (AMPH) vs Moody's Corporation (MCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Moody's Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Moody's Corporation trades at $480.01 (market cap $85.12B). The key difference: Moody's Corporation is far larger — about 103× Amphastar Pharmaceuticals Inc's market cap, and Moody's Corporation pays a 0.85% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MCO | |
|---|---|---|
Market Cap | $826.08M | $85.12B |
Sector | Health | Financials |
52-Week High | $30.81 | $539.61 |
52-Week Low | $16.87 | $412.23 |
Enterprise Value | $1.22B | $90.92B |
Dividend Yield | — | 0.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
MCO trades at $487.28, up 0.05% on the day, with a bullish technical signal supported by moving averages and strong fundamentals. The company reported Q1 2026 EPS of $4.33, beating estimates, and maintains robust profitability with a 31.69% net income margin. Recent news highlights Moody's AI initiatives, including new AI skills and integrations, positioning for growth in credit analytics. The stock is near its 52-week high, with support at $481 and resistance at $490.
Outlook remains positive with a consensus price target of $539.40, implying 11% upside, driven by earnings momentum and AI adoption. Risks include high valuation multiples (P/E 34.96) and dependence on debt issuance cycles. Institutional sentiment is bullish with 56% buy ratings, but overbought RSI levels suggest near-term consolidation potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
